Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium

Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium

Abstract Background Biomarkers may contribute to improved cardiovascular risk estimation. Glycated hemoglobin A1c (HbA1c) is used to monitor the quality of diabetes treatment. Its strength of association with cardiovascular outcomes in the general population remains uncertain. This study aims to ass...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Christoph Sinning, Nataliya Makarova, Henry Völzke, Renate B. Schnabel, Francisco Ojeda, Marcus Dörr, Stephan B. Felix, Wolfgang Koenig, Annette Peters, Wolfgang Rathmann, Ben Schöttker, Hermann Brenner, Giovanni Veronesi, Giancarlo Cesana, Paolo Brambilla, Tarja Palosaari, Kari Kuulasmaa, Inger Njølstad, Ellisiv Bøgeberg Mathiesen, Tom Wilsgaard, Stefan Blankenberg, Stefan Söderberg, Marco M. Ferrario, Barbara Thorand
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Biomarkers
Glycated hemoglobin A1c (HbA1c)
Cardiovascular risk
Mortality
BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe)
MORGAM (MONICA Risk Genetics Archiving and Monograph)
Diseases of the circulatory (Cardiovascular) system
RC666-701
Accès en ligne:https://doaj.org/article/9731035e63df4338aefbcedd86a46c91
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/9731035e63df4338aefbcedd86a46c91

Documents similaires